SCHEMBL5067720

SCHEMBL5067720

Brc1ccc(-c2[c]c3ccccc3[nH]2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.40
MAPT P10636 2/20 0.38
NR1I3 Q14994 1/20 0.38
MAPK13 O15264 3/20 0.37
GCGR P47871 3/20 0.37
MAPK12 P53778 3/20 0.37
MAPK11 Q15759 3/20 0.37
MAPK14 Q16539 3/20 0.37
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972818 0.84 NPC1 (0.41) ALDH1A1MAPK1MAPTTP53CYP19A1
SCHEMBL4600217 0.81 KDM4E (0.47) ALDH1A1MAPTMAPK13MAPK12MAPK11
SCHEMBL11785225 0.80 ALDH1A1 (0.38) ALDH1A1MAPTCDK2HTTTDP1
SCHEMBL7999620 0.73 BRD4 (0.37) ALDH1A1MAPTNR1I3TNKS2TDP1
SCHEMBL7288684 0.71 ALDH1A1 (0.35) ALDH1A1MAPTHTTTDP1SMN1; SMN2
SCHEMBL3662572 0.71 GPR84 (0.42) DRD2CDK1PRKACACSNK2A1CYP1A1
SCHEMBL8697262 0.70 NPC1 (0.42) ALDH1A1MAPK1MAPTKDRHTT
SCHEMBL694769 0.70 LMNA (0.44) ALDH1A1MAPK13MAPK12MAPK11MAPK14
SCHEMBL1492649 0.70 CYP19A1 (0.51) ALDH1A1MAPTTP53CYP19A1HTT
SCHEMBL6336392 0.67 RAB9A (0.53) ALDH1A1MAPTAURKAKDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
EP-1421071-A2 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS NOVO NORDISK A/S (DK) 2004-05-26 EP disclosed
US-20040019039-A1 Substituted piperazines and diazepanes HIGH POINT PHARMACEUTICALS, LLC 2004-01-29 US disclosed
WO-2003004480-A2 SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS NOVO NORDISK A/S (DK) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 ALDH1A1 1907/4885MAPK1 3802/4885MAPT 1441/4885
US-20040019039-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 ALDH1A1 1907/4885MAPK1 3802/4885MAPT 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.